February 16, 2022 – Current Report No. 4/2022 – The KDPW statement on concluding an agreement on the registration of the Company’s series C shares

Legal basis: Article 56 section 1 point 2 Act on Public Offering – current and periodic information.
Date: February 16, 2022.
The abbreviated name of the issuer CELON PHARMA S.A.
Subject: The KDPW statement on concluding an agreement on the registration of the Company's series C shares

The Management Board of Celon Pharma SA (the "Company") hereby informs about the statement issued by the Central Securities Depository of Poland ("KDPW"), on February 15, 2022, on conclusion of an agreement with the Company on the registration of securities in the depository of up to 2,000,000 series C shares of the Company.
Th shares will be registered on the basis of settlement orders referred to in § 6 of the Specific Operating Rules, in connection with deregistration of subscription warrants which were used to exercise the rights of the above-mentioned shares.
Series C shares are issued as part of the contingent capital, pursuant to Resolution No. 7/2021of the General Meeting of Shareholders of February 16, 2021 (current report No. 9/2021).